Smith W, Gore V A, Brandon D R, Lynch D N, Cranstone S A, Corvalan J R
Lilly Research Centre Ltd, Eli Lilly & Co., Windlesham, Surrey, United Kingdom.
Cancer Immunol Immunother. 1990;31(3):157-63. doi: 10.1007/BF01744730.
The hybrid-hybrid monoclonal antibody 28-19-8 has specificity for the tumour-associated antigen carcinoembryonic antigen and the vinca alkaloids. This bifunctional antibody has been used to target unmodified vinblastine sulphate to well-established MAWI human tumour xenografts implanted in nude mice. The highly significant suppression of tumour growth achieved throughout treatment has also been sustained for over 2 months after the withdrawal of treatment. Histological examination of excised tumours from treated animals has shown profound changes in their morphology when compared with tumours from control animals. Cells in tumours that had started to grow again after withdrawal of therapy were shown still to express carcinoembryonic antigen, the target antigen recognised by the bispecific antibody.
杂交-杂交单克隆抗体28-19-8对肿瘤相关抗原癌胚抗原和长春花生物碱具有特异性。这种双功能抗体已被用于将未修饰的硫酸长春碱靶向植入裸鼠体内的成熟MAWI人肿瘤异种移植物。在整个治疗过程中实现的肿瘤生长的高度显著抑制在停止治疗后也持续了2个多月。与对照动物的肿瘤相比，对治疗动物切除肿瘤的组织学检查显示其形态发生了深刻变化。在停止治疗后再次开始生长的肿瘤中的细胞仍显示表达癌胚抗原，即双特异性抗体识别的靶抗原。
